ENDRA, MCW Begin Thermo-acoustic Enhanced US Study for Liver Disease

By News Release

ENDRA Life Sciences Inc. has announced that the Medical College of Wisconsin (MCW) is partnering with ENDRA for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS™) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD).

"We are thrilled that MCW, a renowned research institution and pioneer in liver disease management and transplantation is evaluating TAEUS as a tool to characterize NAFLD, a condition that impacts more than one billion people globally," said ENDRA Life Sciences CEO, Francois Michelon. “It's an honor for ENDRA to garner the clinical interest of another leading research institution. We look forward to building our relationship with MCW as we commercialize TAEUS starting in the second half of this year.”

This represents the third clinical research partnership for ENDRA in the United States and is a natural progression from the feasibility study conducted by the Robarts Research Institute, which used healthy volunteers to establish the safety and efficacy of the TAEUS technology. The data from the MCW study, along with other ongoing or to-be initiated studies, will be used to bolster the clinical evidence and further establish the clinical utility of the TAEUS ultrasound device in patients with NAFLD, as commercialization begins in the second half of the year. The study will be led by Dr. Achuthan Sourianarayanane, MD, MRCP, Assistant Professor at MCW in the Gastroenterology and Hepatology department, practicing at Froedtert Hospital.

“Currently, the options to assess and monitor liver fat in NAFLD patients, namely MRI and liver biopsy, are difficult to integrate into clinical practice. There is a great need for more practical tools to help manage patients with this chronic condition,” said Dr. Sourianarayanane. “We are excited to conduct this study of TAEUS in our patients with NAFLD, and to better understand the potential clinical utility of ENDRA's TAEUS technology.”

The goals of the MCW study, include:

  • Comparing ENDRA's commercial design TAEUS liver device against a baseline measure of liver fat as determined by the current standard of care, MRI-PDFF (magnetic resonance imaging proton density fat fraction).
  • Scanning a target of 75 fatty liver patients to contribute additional diversity and volume of patient data.
  • Providing ENDRA with ongoing clinical feedback on product design and clinical performance.
  • Helping to establish the clinical value proposition of the TAEUS system in NAFLD to support ongoing commercialization efforts.
Back To Top

ENDRA, MCW Begin Thermo-acoustic Enhanced US Study for Liver Disease.  Appl Radiol. 

By News Release| June 09, 2020

About the Author

News Release

News Release

Copyright © Anderson Publishing 2021